Drugs: teclistamab, elranatamab, linvoseltamab
PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies
This article delves into PRAC's assessment of safety signals related to bispecific antibodies, focusing on their efficacy and safety in treating hematologic malignancies.
Intelligence Snapshot
Executive Summary
Main news: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) found no new safety signals related to bispecific antibodies used in hematologic malignancies as of September 2025. This supports continued development and use of these therapies.
Key Insights
-
Clinical impact: The absence of new safety concerns identified by PRAC may build…
Clinical impact: The absence of new safety concerns identified by PRAC may build confidence in the safety profile of bispecific antibodies.
-
Market implications: A stable safety profile could facilitate regulatory confidence and…
Market implications: A stable safety profile could facilitate regulatory confidence and market uptake of bispecific antibodies in the European Union.
-
Next steps: Continuous PRAC safety monitoring will be important for long-term risk…
Next steps: Continuous PRAC safety monitoring will be important for long-term risk management as new bispecific antibodies emerge.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
Key Questions
- What is the role of PRAC in the EU regulatory system?
- What are bispecific antibodies and how do they work?
- What does it mean that PRAC has not identified new safety signals?
- How might the PRAC's findings impact market access in the EU?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for teclistamab.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents11 sections
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 22, 2026
Key Takeaways
- Main news: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) found no new safety signals related to bispecific antibodies used in hematologic malignancies as of September 2025. This supports continued development and use of these therapies.
- Clinical impact: The absence of new safety concerns identified by PRAC may build confidence in the safety profile of bispecific antibodies.
- Market implications: A stable safety profile could facilitate regulatory confidence and market uptake of bispecific antibodies in the European Union.
- Next steps: Continuous PRAC safety monitoring will be important for long-term risk management as new bispecific antibodies emerge.
The EMA bispecific antibody approval landscape remains positive, with the Pharmacovigilance Risk Assessment Committee (PRAC) reporting no new safety signals related to novel bispecific antibodies used in hematologic malignancies. Assessments conducted by PRAC through September 2025 indicate a stable safety profile for these therapies, including those targeting B-cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (RRMM). Why it matters: This confirmation of safety supports continued clinical development and use of bispecific antibodies as a novel targeted immunotherapy approach.
IntelligenceRegulatory Impact
EMA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in Europe. Regulatory relevance reads medium for hematologic malignancies. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.
Drug Overview
Bispecific antibodies represent a class of immunotherapeutic agents engineered to simultaneously bind two different antigens or epitopes. This dual-targeting mechanism enhances targeted immune responses against malignant cells. BCMA-directed bispecific antibodies, for example, target the B-cell maturation antigen expressed on multiple myeloma cells. These antibodies are being developed and used for relapsed/refractory multiple myeloma (RRMM).
IntelligenceCompetitive Intelligence
Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.
Clinical Insights
Currently, there is no specific clinical trial data available regarding the efficacy or safety of bispecific antibodies from the provided facts. However, the PRAC's assessment indicates no new adverse events or safety concerns have been identified in their latest reviews of novel bispecific antibodies in hematologic malignancies through September 2025. This suggests that the existing safety profile of these agents remains consistent.
IntelligenceMarket Signals
Commercial pull is medium for manufacturing capacity, outsourcing, and supply resilience. Investment relevance is low — watch capex, licensing, and regional hub expansion.
Regulatory Context
The PRAC, a committee of the EMA, plays a critical role in pharmacovigilance and the detection of safety signals for medicinal products. As of the latest assessments in July and September 2025, no new adverse events, black-box warnings, Risk Evaluation and Mitigation Strategies (REMS) requirements, or contraindications related to novel bispecific antibodies in hematologic malignancies were identified by PRAC.
IntelligenceStrategic Takeaways
Main news: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) found no new safety signals related to bispecific antibodies used in hematologic malignancies as of September 2025. This supports continued development and use of these therapies. Clinical impact: The absence of new safety concerns identified by PRAC may build confidence in the safety profile of bispecific antibodies. Market implications: A stable safety profile could facilitate regulatory confidence and market uptake of bispecific antibodies in the European Union.
Market Impact
The absence of new safety signals identified by the EMA PRAC may facilitate regulatory confidence and market uptake of bispecific antibodies in hematologic malignancies across the European Union. Bispecific antibodies offer dual antigen targeting, potentially enhancing efficacy compared with monospecific therapies. BCMA-directed bispecific antibodies specifically target multiple myeloma cells, differentiating them from other immunotherapies. The PRAC's confirmation of a stable safety profile could positively influence ongoing and future development and commercialization efforts in this area.
IntelligenceEvidence Quality
Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.
Future Outlook
The field of bispecific antibodies in hematologic oncology continues to evolve, with emerging candidates and ongoing clinical trials. Continuous safety monitoring by the PRAC will be essential for long-term risk management as new bispecific antibodies enter the market. What to watch next: The ongoing development and clinical trials of emerging bispecific antibody candidates in hematologic oncology.
Frequently Asked Questions
What is the role of PRAC in the EU regulatory system?
The Pharmacovigilance Risk Assessment Committee (PRAC) is a committee within the European Medicines Agency (EMA) responsible for assessing and monitoring the safety of medicinal products. It plays a key role in detecting and evaluating safety signals to ensure the benefit-risk balance of medicines is maintained.
What are bispecific antibodies and how do they work?
Bispecific antibodies are a class of immunotherapeutic agents engineered to simultaneously bind two different antigens or epitopes. This dual-targeting mechanism enhances targeted immune responses against malignant cells, offering a novel approach to cancer therapy.
What does it mean that PRAC has not identified new safety signals?
The absence of new safety signals identified by PRAC indicates that, based on the latest assessments, the existing safety profile of the novel bispecific antibodies remains consistent. This suggests stability in the safety profile of these therapies.
How might the PRAC's findings impact market access in the EU?
A stable safety profile, as confirmed by PRAC, may increase regulatory confidence and facilitate market uptake of bispecific antibodies in hematologic malignancies across the European Union. This could positively influence ongoing and future development and commercialization efforts in this area.
References
References
- European Medicines Agency. EMA approval. Accessed 2026-04-22.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About hematologic malignancies
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow teclistamab developments
EMA hematologic malignancies alerts and teclistamab pipeline updates, every Monday.
- Evidence strength
- 71/100
- Last verified
- Jun 15, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Moderate source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
About the Author
Continue Your Research
Industry Reports & Whitepapers
- La Negoziazione del Prezzo dei Farmaci Oncologici in Italia — This whitepaper analyzes the market benchmark role in negotiating oncology drug prices in Italy, hig…
- Cytological Specimens in the Molecular Era of Metastatic Melanoma — This whitepaper discusses the role of cytological specimens in diagnosing metastatic melanoma and th…